Search research articles
Contact Us
Filters
Showing results (71-80 of 755) with videos related to
Page
of 76
Sort By:
Rheumatology (Oxford, England)
|
January 10, 2014
Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets
Daniel E Furst, Paul Emery
Clinics in Rheumatic Diseases
|
April 1, 1986
Implications of drug therapy in the elderly
J Morgan, D E Furst
European Journal of Rheumatology
|
November 9, 2020
The burning question: To use or not to use cyclophosphamide in systemic sclerosis
Cosimo Bruni, Daniel E Furst
Clinical and Experimental Rheumatology
|
December 10, 1999
Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA)
T Münster, D E Furst
Bailliere'S Clinical Rheumatology
|
December 1, 1990
Methotrexate--the rapidly acting drug
N Songsiridej, D E Furst
The Journal of Rheumatology
|
August 3, 2014
Rheumatoid arthritis: are current research-based guidelines clinically relevant?
Suzanne Kafaja, Daniel E Furst
Rheumatology (Oxford, England)
|
April 5, 2008
Autoinflammatory diseases: an update of clinical and genetic aspects
Q Yao, D E Furst
The American Journal of Managed Care
|
April 17, 2008
Health-related quality of life in rheumatoid arthritis
Daniel E Furst, Dinesh Khanna
Rheumatology (Oxford, England)
|
September 17, 2008
Pulmonary function tests
J Behr, D E Furst
Rheumatology (Oxford, England)
|
April 27, 2007
Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?
K Brune, D E Furst
Page
of 76
Search research articles
Search
Showing results (71-80 of 755) with videos related to
Sort By:
Page
of 76
Rheumatology (Oxford, England)
|
January 10, 2014
Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets
Daniel E Furst, Paul Emery
Clinics in Rheumatic Diseases
|
April 1, 1986
Implications of drug therapy in the elderly
J Morgan, D E Furst
European Journal of Rheumatology
|
November 9, 2020
The burning question: To use or not to use cyclophosphamide in systemic sclerosis
Cosimo Bruni, Daniel E Furst
Clinical and Experimental Rheumatology
|
December 10, 1999
Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA)
T Münster, D E Furst
Bailliere'S Clinical Rheumatology
|
December 1, 1990
Methotrexate--the rapidly acting drug
N Songsiridej, D E Furst
The Journal of Rheumatology
|
August 3, 2014
Rheumatoid arthritis: are current research-based guidelines clinically relevant?
Suzanne Kafaja, Daniel E Furst
Rheumatology (Oxford, England)
|
April 5, 2008
Autoinflammatory diseases: an update of clinical and genetic aspects
Q Yao, D E Furst
The American Journal of Managed Care
|
April 17, 2008
Health-related quality of life in rheumatoid arthritis
Daniel E Furst, Dinesh Khanna
Rheumatology (Oxford, England)
|
September 17, 2008
Pulmonary function tests
J Behr, D E Furst
Rheumatology (Oxford, England)
|
April 27, 2007
Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?
K Brune, D E Furst
Page
of 76